Aarti Drugs Limited (BOM:524348)
India · Delayed Price · Currency is INR 375.30
-0.10 (-0.03%)
At close: Feb 12, 2026
Aarti Drugs Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 1,682 | 1,714 | 1,663 | 2,050 | 2,804 |
Depreciation & Amortization | 541.94 | 510.48 | 501.28 | 500.08 | 487.08 |
Other Amortization | 15.83 | 3.99 | 1.96 | 0.41 | 11.76 |
Loss (Gain) From Sale of Assets | -0.3 | 1.83 | -1.11 | -0.17 | -32.67 |
Asset Writedown & Restructuring Costs | 12.32 | - | - | - | 30.42 |
Loss (Gain) From Sale of Investments | -2.71 | 2.92 | - | - | - |
Provision & Write-off of Bad Debts | 37.22 | 18.96 | 7.59 | 16.87 | 8.47 |
Other Operating Activities | 124.08 | 309.02 | 323.77 | 10.09 | 100.24 |
Change in Accounts Receivable | 343.5 | 1,611 | -944.22 | -1,939 | -654.19 |
Change in Inventory | 129.64 | 342.46 | 58.22 | -1,106 | -891.85 |
Change in Accounts Payable | -437.26 | -925.31 | -277.37 | 1,171 | -313.88 |
Operating Cash Flow | 2,446 | 3,589 | 1,333 | 704.14 | 1,550 |
Operating Cash Flow Growth | -31.86% | 169.22% | 89.34% | -54.56% | -38.20% |
Capital Expenditures | -1,772 | -2,263 | -1,648 | -1,520 | -882.31 |
Sale of Property, Plant & Equipment | 0.48 | 1.87 | 1.45 | 0.2 | 108.86 |
Investment in Securities | 2.71 | - | - | - | - |
Other Investing Activities | 122.12 | 24.97 | 7 | 23.15 | 55.66 |
Investing Cash Flow | -1,646 | -2,237 | -1,640 | -1,496 | -717.8 |
Short-Term Debt Issued | 409.24 | - | 13.97 | 2,028 | - |
Long-Term Debt Issued | 702.4 | 1,482 | 1,158 | - | - |
Total Debt Issued | 1,112 | 1,482 | 1,172 | 2,028 | - |
Short-Term Debt Repaid | - | -1,245 | - | - | - |
Long-Term Debt Repaid | -776.08 | -459.36 | -558.61 | -68.69 | -349.67 |
Total Debt Repaid | -776.08 | -1,705 | -558.61 | -68.69 | -349.67 |
Net Debt Issued (Repaid) | 335.56 | -222.85 | 613.74 | 1,959 | -349.67 |
Issuance of Common Stock | - | - | 7.56 | - | - |
Repurchase of Common Stock | -731.73 | -731.73 | - | -738.38 | - |
Common Dividends Paid | -90.61 | -92.67 | -94.01 | -95.08 | -232.05 |
Other Financing Activities | -334.41 | -313.08 | -361.86 | -205.78 | -229.57 |
Financing Cash Flow | -821.19 | -1,360 | 165.42 | 920.25 | -811.29 |
Miscellaneous Cash Flow Adjustments | 0 | - | - | -0 | - |
Net Cash Flow | -21.65 | -7.61 | -141.09 | 127.99 | 20.42 |
Free Cash Flow | 674.22 | 1,326 | -314.97 | -815.61 | 667.19 |
Free Cash Flow Growth | -49.15% | - | - | - | -67.09% |
Free Cash Flow Margin | 2.83% | 5.24% | -1.16% | -3.28% | 3.10% |
Free Cash Flow Per Share | 7.39 | 14.42 | -3.40 | -8.81 | 7.16 |
Cash Interest Paid | 334.4 | 313.08 | 361.86 | 205.79 | 229.57 |
Cash Income Tax Paid | 551.17 | 624 | 596.75 | 833.77 | 966.75 |
Levered Free Cash Flow | -150.24 | 1,028 | -802.36 | -1,169 | 150.05 |
Unlevered Free Cash Flow | 73.96 | 1,237 | -594.28 | -1,040 | 293.54 |
Change in Working Capital | 35.88 | 1,028 | -1,163 | -1,874 | -1,860 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.